The European pen needle market is anticipated to grow at a CAGR of 7.7% during the forecast period (2020-2026). The growth of the market is attributed to the easy availability of such devices owing to the strong presence of various global companies such as B. Braun Melsungen AG, Novo Nordisk A/S, Smiths Group Plc., and Vygon SA.
Additionally, the significant increase in the number of diabetes cases in the region is driving more individuals towards insulin that can be self-taken using an insulin pen. Therefore, the adoption of pen needles among individuals is rising across the region as these are convenient as compared to ordinary needles, syringes, and vials, thus driving the growth of the market during the forecast period.
Browse the full report description of "European Pen Needle Market Size, Share & Trends Analysis Report By Type (Standard and Safety), By Therapy (Insulin, GLP-1, Growth Hormones), By Mode of Purchase (Retail and Non-Retail), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/european-pen-needle-market
Moreover, the surge in awareness related to the damage caused by needlestick injuries propels the growth of this market. These injuries result in the transmission of lethal diseases such as HIV, hepatitis B, hepatitis C, among others. Additionally, the high awareness of the pen needle in the region is also aiding to the significant growth of the market. Since, according to the Endocrine Society, pen needles comprise up to 75.0% of insulin prescriptions.
Market Coverage
o By Type
o By Therapy
o By Mode of Purchase
Key questions addressed by the report
European Pen Needle Market Report Segment
By Type
By Therapy
By Mode of Purchase
European Pen Needle Market Report- Countries Covered